Clinical Trial Update: Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 dose-escalation study of continuous once-daily BIBW 2992 (afatinib) in patients with advanced solid tumors, fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• BIBW 2992 (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neoplasms | Phase 1 | Status: COMPLETED